Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Smolen

Showing results (31-40 of 863) with videos related to

Pageof 87
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|December 12, 2003
Objectives and strategies for rheumatoid arthritis therapy: yesterday vs. todayJosef S Smolen
Health Progress (Saint Louis, Mo.)|June 8, 1991
The action approach. Integrating a community's needs into the corporate planning processS Smolen, C Quigley
Clinical and Experimental Rheumatology|June 26, 2010
The assessment of disease activity in rheumatoid arthritisJosef S Smolen, Daniel Aletaha
Lupus|July 3, 2004
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic interventionM Aringer, J S Smolen
Annals of the Rheumatic Diseases|March 6, 2021
Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday <i>et al</i>Peter Nash, Josef S Smolen
Clinical and Experimental Rheumatology|October 17, 2015
Treatment of psoriatic arthritis: management recommendationsLaure Gossec, Josef S Smolen
Current Rheumatology Reports|September 12, 2003
The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical careJosef S Smolen, Daniel Aletaha
Arthritis and Rheumatism|October 23, 2001
Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritisJ S Smolen, G Steiner
Nature Reviews. Rheumatology|August 21, 2019
Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targetsDaniel Aletaha, Josef S Smolen
Current Opinion in Rheumatology|April 5, 2008
Activity assessments in rheumatoid arthritisJosef S Smolen, Daniel Aletaha
Pageof 87

Showing results (31-40 of 863) with videos related to

Sort By:
Pageof 87
Drugs of Today (Barcelona, Spain : 1998)|December 12, 2003
Objectives and strategies for rheumatoid arthritis therapy: yesterday vs. todayJosef S Smolen
Health Progress (Saint Louis, Mo.)|June 8, 1991
The action approach. Integrating a community's needs into the corporate planning processS Smolen, C Quigley
Clinical and Experimental Rheumatology|June 26, 2010
The assessment of disease activity in rheumatoid arthritisJosef S Smolen, Daniel Aletaha
Lupus|July 3, 2004
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic interventionM Aringer, J S Smolen
Annals of the Rheumatic Diseases|March 6, 2021
Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday <i>et al</i>Peter Nash, Josef S Smolen
Clinical and Experimental Rheumatology|October 17, 2015
Treatment of psoriatic arthritis: management recommendationsLaure Gossec, Josef S Smolen
Current Rheumatology Reports|September 12, 2003
The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical careJosef S Smolen, Daniel Aletaha
Arthritis and Rheumatism|October 23, 2001
Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritisJ S Smolen, G Steiner
Nature Reviews. Rheumatology|August 21, 2019
Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targetsDaniel Aletaha, Josef S Smolen
Current Opinion in Rheumatology|April 5, 2008
Activity assessments in rheumatoid arthritisJosef S Smolen, Daniel Aletaha
Pageof 87